ENTRADA THERAPEUTICS INC (TRDA) Fundamental Analysis & Valuation

NASDAQ:TRDA • US29384C1080

Current stock price

11.93 USD
-0.38 (-3.09%)
At close:
11.93 USD
0 (0%)
After Hours:

This TRDA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. TRDA Profitability Analysis

1.1 Basic Checks

  • In the past year TRDA has reported negative net income.
  • In the past year TRDA has reported a negative cash flow from operations.
  • TRDA had negative earnings in 4 of the past 5 years.
  • In the past 5 years TRDA reported 4 times negative operating cash flow.
TRDA Yearly Net Income VS EBIT VS OCF VS FCFTRDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M -150M

1.2 Ratios

  • TRDA has a Return On Assets (-38.09%) which is comparable to the rest of the industry.
  • The Return On Equity of TRDA (-46.96%) is better than 66.09% of its industry peers.
Industry RankSector Rank
ROA -38.09%
ROE -46.96%
ROIC N/A
ROA(3y)-9.02%
ROA(5y)-16.26%
ROE(3y)-11.47%
ROE(5y)-19.21%
ROIC(3y)N/A
ROIC(5y)N/A
TRDA Yearly ROA, ROE, ROICTRDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60

1.3 Margins

  • TRDA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRDA Yearly Profit, Operating, Gross MarginsTRDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. TRDA Health Analysis

2.1 Basic Checks

  • TRDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TRDA has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for TRDA has been increased compared to 5 years ago.
  • There is no outstanding debt for TRDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TRDA Yearly Shares OutstandingTRDA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
TRDA Yearly Total Debt VS Total AssetsTRDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • TRDA has an Altman-Z score of 2.54. This is not the best score and indicates that TRDA is in the grey zone with still only limited risk for bankruptcy at the moment.
  • TRDA has a Altman-Z score of 2.54. This is in the better half of the industry: TRDA outperforms 66.09% of its industry peers.
  • There is no outstanding debt for TRDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.54
ROIC/WACCN/A
WACC9.35%
TRDA Yearly LT Debt VS Equity VS FCFTRDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M 400M

2.3 Liquidity

  • TRDA has a Current Ratio of 12.53. This indicates that TRDA is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 12.53, TRDA belongs to the top of the industry, outperforming 86.51% of the companies in the same industry.
  • TRDA has a Quick Ratio of 12.53. This indicates that TRDA is financially healthy and has no problem in meeting its short term obligations.
  • TRDA's Quick ratio of 12.53 is amongst the best of the industry. TRDA outperforms 86.51% of its industry peers.
Industry RankSector Rank
Current Ratio 12.53
Quick Ratio 12.53
TRDA Yearly Current Assets VS Current LiabilitesTRDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. TRDA Growth Analysis

3.1 Past

  • TRDA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -281.15%.
  • Looking at the last year, TRDA shows a very negative growth in Revenue. The Revenue has decreased by -87.94% in the last year.
EPS 1Y (TTM)-281.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3233.33%
Revenue 1Y (TTM)-87.94%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-96.53%

3.2 Future

  • TRDA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.49% yearly.
  • The Revenue is expected to grow by 46.56% on average over the next years. This is a very strong growth
EPS Next Y-14.21%
EPS Next 2Y-5.45%
EPS Next 3Y-0.93%
EPS Next 5Y6.49%
Revenue Next Year14.56%
Revenue Next 2Y31.43%
Revenue Next 3Y29.85%
Revenue Next 5Y46.56%

3.3 Evolution

TRDA Yearly Revenue VS EstimatesTRDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
TRDA Yearly EPS VS EstimatesTRDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

0

4. TRDA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TRDA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TRDA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRDA Price Earnings VS Forward Price EarningsTRDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRDA Per share dataTRDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.45%
EPS Next 3Y-0.93%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TRDA Dividend Analysis

5.1 Amount

  • No dividends for TRDA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TRDA Fundamentals: All Metrics, Ratios and Statistics

ENTRADA THERAPEUTICS INC

NASDAQ:TRDA (3/27/2026, 8:00:01 PM)

After market: 11.93 0 (0%)

11.93

-0.38 (-3.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners74.08%
Inst Owner Change1.15%
Ins Owners0.73%
Ins Owner Change-0.55%
Market Cap456.68M
Revenue(TTM)25.42M
Net Income(TTM)-143.75M
Analysts86.15
Price Target18.87 (58.17%)
Short Float %2.5%
Short Ratio3.53
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.65%
Min EPS beat(2)-10.55%
Max EPS beat(2)19.86%
EPS beat(4)2
Avg EPS beat(4)9.2%
Min EPS beat(4)-20.31%
Max EPS beat(4)47.81%
EPS beat(8)6
Avg EPS beat(8)169.29%
EPS beat(12)7
Avg EPS beat(12)115.74%
EPS beat(16)8
Avg EPS beat(16)86.78%
Revenue beat(2)0
Avg Revenue beat(2)-88.39%
Min Revenue beat(2)-88.45%
Max Revenue beat(2)-88.33%
Revenue beat(4)1
Avg Revenue beat(4)-39.7%
Min Revenue beat(4)-88.45%
Max Revenue beat(4)98.17%
Revenue beat(8)5
Avg Revenue beat(8)58.11%
Revenue beat(12)8
Avg Revenue beat(12)73.98%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.78%
PT rev (3m)12.12%
EPS NQ rev (1m)-1.98%
EPS NQ rev (3m)-1.98%
EPS NY rev (1m)7.65%
EPS NY rev (3m)6.24%
Revenue NQ rev (1m)-81.45%
Revenue NQ rev (3m)-81.45%
Revenue NY rev (1m)-7.53%
Revenue NY rev (3m)3.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.96
P/FCF N/A
P/OCF N/A
P/B 1.49
P/tB 1.49
EV/EBITDA N/A
EPS(TTM)-3.46
EYN/A
EPS(NY)-3.95
Fwd EYN/A
FCF(TTM)-3.38
FCFYN/A
OCF(TTM)-3.36
OCFYN/A
SpS0.66
BVpS8
TBVpS8
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -38.09%
ROE -46.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-9.02%
ROA(5y)-16.26%
ROE(3y)-11.47%
ROE(5y)-19.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.42%
Cap/Sales 4.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.53
Quick Ratio 12.53
Altman-Z 2.54
F-Score3
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)102.24%
Cap/Depr(5y)173.55%
Cap/Sales(3y)3.31%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-281.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3233.33%
EPS Next Y-14.21%
EPS Next 2Y-5.45%
EPS Next 3Y-0.93%
EPS Next 5Y6.49%
Revenue 1Y (TTM)-87.94%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-96.53%
Revenue Next Year14.56%
Revenue Next 2Y31.43%
Revenue Next 3Y29.85%
Revenue Next 5Y46.56%
EBIT growth 1Y-441.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.21%
EBIT Next 3Y-28.1%
EBIT Next 5YN/A
FCF growth 1Y-189.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-209.24%
OCF growth 3YN/A
OCF growth 5YN/A

ENTRADA THERAPEUTICS INC / TRDA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ENTRADA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to TRDA.


What is the valuation status for TRDA stock?

ChartMill assigns a valuation rating of 0 / 10 to ENTRADA THERAPEUTICS INC (TRDA). This can be considered as Overvalued.


How profitable is ENTRADA THERAPEUTICS INC (TRDA) stock?

ENTRADA THERAPEUTICS INC (TRDA) has a profitability rating of 1 / 10.


What is the financial health of ENTRADA THERAPEUTICS INC (TRDA) stock?

The financial health rating of ENTRADA THERAPEUTICS INC (TRDA) is 8 / 10.